| Applications: |
Immunodepletion/Immunocompetition |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
MAP3K8 Blocking Peptide for STJ501677 is synthetically produced from the 360-467 sequence and is suitable for use in western blot applications. |
| Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Gene Symbol: |
MAP3K8 |
| Gene ID: |
1326 |
| Uniprot ID: |
M3K8_HUMAN |
| Immunogen Region: |
360-467 |
| Specificity: |
This blocking peptide is recommended for use in combination with MAP3K8 antibody, STJ501677 |
| Immunogen: |
Synthetic peptide taken within amino acid region 360-467 on human MAP3K8 protein. |
| Tissue Specificity | Expressed in several normal tissues and human tumor-derived cell lines. |
| Post Translational Modifications | Autophosphorylated. Isoform 1 undergoes phosphorylation mainly on Ser residues, and isoform 2 on both Ser and Thr residues. Phosphorylated on Thr-290.the phosphorylation is necessary but not sufficient for full kinase activity in vitro and for the dissociation of isoform 1 from NFKB1, leading to its degradation. Phosphorylated on Ser-400 by IKBKB.the phosphorylation is required for LPS-stimulated activation of the MAPK/ERK pathway in macrophages. |
| Function | Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the pro-inflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant. |
| Peptide Name | Mitogen-Activated Protein Kinase Kinase Kinase 8Cancer Osaka Thyroid OncogeneProto-Oncogene C-CotSerine/Threonine-Protein Kinase CotTumor Progression Locus 2Tpl-2 |
| Database Links | Reactome: R-HSA-389357Reactome: R-HSA-5684264 |
| Cellular Localisation | Cytoplasm |
| Alternative Peptide Names | Mitogen-Activated Protein Kinase Kinase Kinase 8 proteinCancer Osaka Thyroid Oncogene proteinProto-Oncogene C-Cot proteinSerine/Threonine-Protein Kinase Cot proteinTumor Progression Locus 2 proteinTpl-2 proteinMAP3K8 proteinCOT proteinESTF protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
